The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Challenges with defining fitness in CLL & important comorbidities to consider when selecting therapy
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, briefly discusses the challenges with defining fitness in chronic lymphocytic leukemia (CLL), and further comments on important comorbidities to consider when selecting first-line therapy, including cardiovascular health and renal function. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly
Speaker bureau: Octapharma
